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nificantly lower all-cause mortality rate (14.4% vs 51.7%, p< 0.001), fewer total hos-
pitalizations (p< 0.001) and fewer hospitalizations due to cardiovascular problems 
(p< 0.001) were observed in patients discharged with statins. LDL-C goal attainment 
of < 100 mg/dL (2.6 mmol/L) resulted in a significant reduction in mortality (10.8% vs 
24.2%, p= 0.001), but not for goal attainment of < 70 mg/dL (1.8 mmol/L). Significant 
difference in survival existed only when LDL-C cut-off values were above 92 mg/dL 
(2.4 mmol/L). ConClusions: This study revealed a J-curve phenomenon in ACS 
patients of Hong Kong. Further research should be conducted to assess the necessity 
of aggressive LDL-C reduction to < 70 mg/dL (1.8 mmol/L).
HEALTH CARE REIMBURSEMENT STUDIES
HC1
IMpACT EvALUATIoN of pRovIDER pAyMENT REfoRM UNDER THE NEw 
RURAL CoopERATIvE MEDICAL SCHEME IN GANSU pRovINCE, CHINA
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objeCtives: The New Cooperative Medical Scheme (NCMS) which aims to reduce 
the risk of catastrophic health spending for rural residents has substantially 
improved health care access and utilization in China. However, cost containment 
and provider incentive remains a huge challenge, which has been particularly acute 
in poorer rural areas, such as the North-west. Over the past years, several coun-
ties in Gansu province have introduced a variety of provider payment reforms, 
shifting from the traditional Fee-for-Service to case-based, global budget  and/
or per-diem  methods. This study provides the first impact evaluation of these 
reforms. Methods: Using a quasi-experimental design, we collected NCMS claims 
data from 2008 to 2013 in three counties. A difference-in-difference analysis is per-
formed to take advantage of the variation in provider payment methods imple-
mented at different years across the counties. We also control for patients’ age, 
gender and diagnosis as well as demographic factor of each county in estimating the 
effects of payment reform on cost (measured by inpatient health care expenditure) 
and quality (measured by readmission rate). In addition to the quantitative analysis, 
we conduct key informant interviews with policymakers, hospital administrators, 
and medical professionals to better understand the design and implementation 
issues involved in the reform process. Results: Preliminary data analysis indicates 
that in one county, the provider payment reform is associated with 9.8% drop in total 
health care expenditure per admission. Length of stay fell by 4.9% as a result too.  
However, other factors such as changes in the demand-side reimbursement rate 
may also influence the outcomes. Differences in local infrastructure and technical 
capacity have led to the same payment method implemented differently at the 
county level. ConClusions: Provider payment reform in rural China can be an 
effective way to control health expenditure. However, more technical guidance on 
designing the right payment is needed for future reforms.
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objeCtives: Single pill combinations (SPC) are associated with improved adherence 
and persistence in hypertensive (HTN) populations. High adherence and persistence 
can provide medical benefit for patients and reduce the total health care utiliza-
tion and costs. This study investigated if Exforge HCT is associated with reduced 
health care utilization and costs during the 12 months follow up period in adult 
hypertensive (HTN) patients adherent to treatment. Methods: A retrospective 
cohort study was conducted including adult (18 yrs. or older) HTN patients covered 
by commercial and Medicare Supplemental insurance in the Truven MarketScan 
database with an HTN diagnosis between October 2009 and December 2011. At 
least two filled prescriptions for Exforge HCT or two periods of minimum 15 days 
of concurrent use of amlodipine, valsartan and hydrochlorothiazide (FC cohort), 
and at least 80% Medication Possession Ratio(MPR) were required. Chi-Square tests 
and independent sample t-tests were used after propensity score matching (PSM) 
(absolute standardized differences (ASM) < 0.1) using demographics, comorbidi-
ties, pre-index HRU, pre-index costs and valsartan initial dose. Results: Adherent 
Exforge HCT patients (N= 6,004) had better outcomes compared to adherent FC 
patients (N= 1,084) in the 12 months follow up period: less all cause hospitalization 
(9.2% vs 16.6%, p< 0.05; Mean 0.1 vs 0.2, p< 0.0001), less all cause ER visits(19.0% vs 
29.3%, p< 0.05; Mean 0.3 vs 0.6, p< 0.0001), less HTN specific ER visits(7.0% vs 12.0%, 
p< 0.05; Mean 0.1 vs 0.2, p< 0.0001), less total medical service cost(7247$ vs $10370, 
p< 0.0001), less total prescription drug costs(3926$ vs $5350, p< 0.0001) and less total 
health care costs($11173 vs $15720, p< 0.0001). After applied PSM, adherent Exforge 
HCT patients still had lower proportion of all cause hospitalization, all cause ER 
visit and less number of all prescriptions, p< 0.05. ConClusions: Real-world data 
indicate that Exforge HCT is associated with less health care utilization and costs 
compared to amlodipine/valsartan/hydrochlorothiazide FC among patients with 
adherent treatment of HTN.
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objeCtives: Generic entry of pharmaceuticals in Australia triggers a price reduc-
tion of 16%, followed by further reductions via a process called ‘Price Disclosure’ 
(PD).  Significant price reductions for standard of care (SOC) derived through PD 
groups. ConClusions: No statistically significant difference in the effectiveness 
of oral Ibuprofen and oral Indomethacin compared to the intravenous NSAIDs with 
similar adverse outcome were observed. Oral formulations of Indomethacin and 
Ibuprofen might be considered as an alternative pharmacologic closure in PDA 
treatment for the NICU settings where intravenous NSAIDs is unavailable.
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objeCtives: To evaluate the management of ischaemic stroke (IS) patients enrolled 
in the Japan Stroke Databank (JSD) from 2000 to 2007. Methods: JSD is an obser-
vational registry of patients who experienced a stroke event, collecting patient 
information provided by over 80 Japanese hospital departments. Data included 
demographics, time to admission, medical history, stroke type diagnosis, imaging, 
treatment,  Japan Stroke Scale (JSS), NIH Stroke Scale (NIHSS) and the modified 
Rankin Scale (m-RS). Logistic regression model was used to identify predictors of 
m-RS 0-1 at discharge. Results: Of the 47,782 stroke patients, when excluding for 
transient ischemic attack (TIA) cases, 15,282 (32%) were ischaemic stroke cases with 
NIHSS evaluation at hospitalization and at discharge and with m-RS assessment 
at discharge. Average age was 69.7 years (±10.6) and 64% were males. Patients who 
were admitted to hospital at a later time window from onset had a lower m-RS score 
(0-1) at admission (12%, 13%, 15% and 17% for patients admitted at 0-3, 3-4.5, 4.5-8 
and 8-24 hours , respectively). However, patients admitted at later time-windows 
had worse disability at discharge (within patients admitted with m-RS 0-1, 53% vs. 
48% had m-RS 0 at discharge depending if admitted before or after 3 hours after 
onset). 57% of patients arrived after 3 hours and only 5.8% received thrombolytic 
treatment (2.1% received alteplase and the remaining received urokinase). Non-
significant severity at baseline and alteplase with edaravone lowered the odds of 
severity at discharge. ConClusions: This study demonstrates that despite the 
availabilities of therapies for acute ischemic stroke there is still a high unmet need 
to reduce severity at discharge for these patients as only 5.8 % of patients receive 
thrombolytic therapy.
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objeCtives: As the international guidance for lipid control has evolved, the 
National Health Insurance Administration (NHIA) in Taiwan was requested to 
modify the current reimbursement criteria for initiation of lipid-lowering treatment. 
The study aims to evaluate the cost-effectiveness and the budget impact of the 
newly proposed reimbursement criteria on lipid-lowering drug from the NHIA’s 
viewpoint with a focus on the change of statins usage. Methods: In the new cri-
teria, the cut-off points of low-density lipoprotein cholesterol (LDL-C) and total 
cholesterol for initiating lipid-lowering therapy for patients having diabetes or previ-
ous heart diseases (high risk group) have been lowered. A Markov decision model 
was constructed to examine the cost-effectiveness of the new criteria compared 
with the original ones. The efficacy of statins on coronary heart diseases (CHD) 
and stroke was obtained from the literature. The numbers of subjects who may be 
affected by these criteria changes and the LDL-C specific disease transition prob-
abilities were obtained from a population-based survey conducted by the Taiwan 
Health Promotion Administration (HPA). Medical costs were derived from the NHI 
data. Both costs and health outcomes were discounted at 3%. The corresponding 
financial impact on NHI expenditure was also estimated. Results: If the new crite-
ria are applied, the number of subjects who fulfill the reimbursement criteria in the 
high risk group will be almost twice as many as before. This would lead to an great 
increase in the NHI expenditures for statins and monitoring costs, however, this 
could be offset by the treatment cost saved from the averted CHD and stroke cases. 
Therefore, the new criteria are a dominant strategy compared with the original cri-
teria. ConClusions: Although the newly proposed reimbursement criteria would 
lead to an increase in drug expenditure of NHIA, it is expected to be a cost-saving 
strategy after taking into account the health benefit on preventing CHD and stroke.
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objeCtives: The current study primarily aimed to assess the current prescribing 
pattern of lipid-lowering agents and the percentage of LDL-C goal attainment in 
myocardial infarction (MI) patients in local practice, and to evaluate clinical out-
comes of patients stratified by prescription of statins and by LDL-C level attained 
after discharge. Methods: We retrospectively reviewed 696 hospitalized patients 
in the local ACS registry of Prince of Wales Hospital during 1 January 2008 to 31 
December 2009 with data retrieved using computerized clinical records of all 
patients. Results: Among the 402 MI patients included, 104 (25.9%) were not pre-
scribed with statins at discharge. Percutaneous coronary intervention (PCI) per-
formed or planned during hospitalization (OR: 0.324, p= 0.001) and latest LDL-C level 
before discharge (OR: 0.221 for an increment of 1 mmol/L, p= 0.009) were significant 
independent predictors of the absence of statin prescriptions at discharge. A sig-
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ity. ConClusions: FU and MW are common physical therapies for cervical ectopy. 
But the available evidence suggested that FU is more safe and effectiveness than 
MW for treating cervical ectopy and preventing STIs. However, potential publication 
bias and low quality evidence will reduce the reliability of our results. More careful 
designed studies are needed to provide further clarification.
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EffECT of vACCINATIoN AGE oN CoST-EffECTIvENESS of HUMAN 
pApILLoMAvIRUS vACCINATIoN AGAINST CERvICAL CANCER IN CHINA
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objeCtives: The cost-effectiveness (CE) of human papillomavirus (HPV) vaccination 
in women pre-sexual debut has been demonstrated in many countries. The aim of 
this study is to estimate the CE of a 3-dose bivalent HPV vaccination at ages 12 to 55 
year in both rural and urban settings in China. Methods: A previously published 
Markov cohort model was adapted to the Chinese setting, simulating the natural 
history of HPV infection and including the effect of screening and HPV vaccination 
over the lifetime of a 100,000 female cohort for ages 12 to 55 in rural and urban 
China. Transition probabilities and utilities were obtained from published literature. 
Cost data were estimated by Delphi panel using health care payers’ perspective. 
Vaccine cost was assumed  Hong Kong listed price. Vaccine efficacy (VE) was based 
on the PATRICIA trial data assuming VE irrespective of HPV type at all ages on inci-
dent HPV. Costs and outcomes were discounted at 3%. Cervical cancer (CC) cases 
and incremental cost-effectiveness ratio (ICER) for vaccination and screening com-
pared with screening alone were estimated for each vaccination age. Reduced VE in 
women post-sexual debut were investigated in scenario analyses. Results: With 
70% vaccination coverage, a reduction of CC cases varying from 585 to 33 in rural and 
691 to 32 in urban were estimated at ages 12 to 55, respectively. Vaccination remains 
CE up to age 23 in rural and age 25 in urban, as the discounted ICERs were lower 
than the current threshold (3×national GDP 2013/capita=20,292USD, 125,723RMB). 
Scenario analyses with lower VE post-sexual debut confirmed the results with age 
20 in rural and 21 in urban to remain CE. ConClusions: HPV vaccination program 
in girls before age 23 in rural and 25 in urban setting was shown to be cost-effective 
strategies for the prevention of CC in China.
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objeCtives: To evaluate the cost-effectiveness of caspofungin versus C-AmB for 
empirical antifungal therapy in patients with neutropenic fever from health care 
provider perspective in Thailand. Methods: A decision-analytic model was used 
to project costs and outcomes of caspofungin versus C-AmB from treatment initia-
tion until hospital discharge. Since there has not been a head-to-head compara-
tive trial, an indirect treatment comparison was developed based on clinical trials 
that used the same 5-end point composite outcomes, including resolution of fever, 
resolution of baseline infection, absence of breakthrough infection, survival and 
no premature discontinuation. Patients were stratified by the presence or absence 
of baseline infection. Discontinuation because of nephrotoxicity or other adverse 
events were included in the model. Efficacy and safety data were based on Walsh 
2004 (Scenario I) and Walsh 1999 (Scenario II). Life expectancy, quality of life, medical 
resource utilization and disease-related costs were obtained from the literatures 
and expert opinion. Drug prices were those published by Ministry of Public Health. 
All costs were expressed in THB 2013 values. Results: Treatment with caspofungin 
increased life expectancy (LY) by 0.87 and 0.58 years, and resulted in additional 0.63 
and 0.41 quality-adjusted life years (QALYS) when compared to C-AmB in Scenario 
I and II, respectively. In the base-case, use of caspofungin was cost saving in both 
scenarios. The results showed that caspofungin is cost-saving as long as the cost 
of treating nephrotoxicity is higher than 316,830 and 299,762 THB for the respective 
scenarios. The incremental cost-effectiveness ratio (ICER) increases if the cost of 
treating nephrotoxicity or the relative rate of nephrotoxicity decreases. Probabilistic 
sensitivity analysis supported the robustness of these findings. ConClusions: 
This is the first cost-effectiveness   of caspofungin as empirical treatment in 
Thailand. Caspofungin is more effective and less costly compared to C-AmB, and 
the use of caspofungin is anticipated to have both budgetary and health benefits.
IN4
IMpACT of MATERNAL EDUCATIoN oN CHILD IMMUNIzATIoN pRopENSITy  
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objeCtives: To estimate the effects of maternal education and other associ-
ated factors on the immunization propensity for children and adolescents in 
China. Methods: A longitudinal survey (China Health and Nutritional Survey) 
between 1991 and 2006 were used to analyze the relationship between the immu-
nization receipt status and the potential determinants, including children’ char-
acteristics, the household’ characteristics and the community level influences. 
The recommended immunization schedule for persons aged 0 through 18 in 
China is similar to that from Centers for Disease Control and Prevention in the 
U.S. Descriptive statistics were reported for the sample from 9 provinces of China 
in each wave of surveys. Econometric models were constructed with an indicator 
for immunization propensity as the dependent variable (i.e., any immunization 
received by your children during the past 12 months). Independent variables include 
children’s age, gender, whether preventive health care services covered by insur-
ance, their parents’ education level, the household income, transportation time to 
may increase the difficulty of demonstrating cost-effectiveness of a new treat-
ment (NEW).  Conversely, anticipating generic entry for NEW may improve cost-
effectiveness, particularly if initially of high-cost.  The objective of this study was 
to quantify the impact of anticipated PD on reimbursement decision making in 
the Australian context via multi-cohort cost-effectiveness analysis. Methods: A 
two state oncology model was constructed comparing NEW to SOC over 30-years. 
Probability of survival was assumed to be 3-times higher for NEW at 150-times 
the price of SOC. A price function, based on Australian PD statistics, was applied 
to the price of NEW from year 10 to emulate generic entry.  30 cohorts were run 
through the model, each commencing in subsequent years.  ICERs for each cohort 
and an aggregate ICER across all cohorts were calculated.  Whilst no ICER thresh-
old is applied in Australia, $50k/LY was assumed for analysis purposes. Results: 
For individual cohorts, the cost-effectiveness of NEW improved over time.  ICERs 
ranged from $71K/LY for Cohort 1 to $100/LY for Cohort 22 onwards.  The threshold 
was crossed between Cohort 10 and 11.  For all cohorts over 30 years the aggregate 
ICER was $39K/LY, however only 19 cohorts were required over as many years to 
cross the threshold at an ICER of $49K/LY. ConClusions: TTraditional CEA only 
supports funding of NEW from Cohort 11 onward, suggesting a potential 10 year 
delay to access.  Aggregate CEA however supports funding of NEW immediately 
over a time-horizon of 19 or more years.  Clearly future price changes affect CEA of 
new treatments; failure to appropriately account for them may result in delayed 
access to new medications.
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objeCtives: China spent approximately $150 billion US dollars on prescription 
drugs in 2010, accounting for 47% of its annual health expenditures, which has 
attracted worldwide attention. To investigate the causes of rising drug spend-
ing in China, we decomposed drug expenditures to document reasons for this 
event. Methods: Records of 209,758 inpatients were collected from Urban 
Employee Basic Medical Insurance system covering 626 hospitals and 545 health 
care community centers from 2006 to 2010 in Tianjin, China. We found that 264 anti-
infective drug products with 79 ingredients from 16 narrow therapeutic categories 
were calculated using three and six-factor exponential analysis and index-theoret-
ical methodology. In three-factor analysis, drug expenditure was decomposed into 
quantity effect, price effect and therapeutic choice. To further explore underlying 
cause of drug spending soaring, six-factor exponential methodology was applied to 
measure the change and contribution of each dominant. Results: Using exponen-
tial-based decomposition analysis to elucidate important factors driving prescrip-
tion drugs expenditure growth (which increased 163% during five years), we found 
that quantity effect and therapeutic choice increased by 71% and 45% respectively 
and price effect increased by 6% only. Six-factor analysis revealed that 2010 inpatient 
admission volumes increased 76% and this was the most critical spending driver. 
Therapeutic mix and drug mix within the therapeutic choice was the second most 
important factor (36%) and the third (14%) factor among these factors. In contrast, 
pure unit price was a negative factor (declined 10%) with respect to drug expen-
ditures. ConClusions: The selection of more innovative/more expensive drugs 
over older/less expensive therapies dominated drug expenditure growth. Inpatient 
admission patterns and clinical prescription behavior should be a focus of drug 
spending controls. Health providers, insurance agencies, and policy makers can use 
these data to systematically intervene in health care service improvements instead 
of solely focusing on drug price regulations.
INfECTIoUS DISEASE oUTCoMES RESEARCH STUDIES
IN1
CoMpARATIvE SAfETy AND EffICACy of foCUSED ULTRASoUND foR 
CERvICAL ECTopy: A META ANALySES wITH 16180 pATIENTS
Tang X, Yu J, Li Y, Li X
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bACkgRound: Sexually transmitted infections(STIs) are serious public health prob-
lems and lead to tremendous burden of health and economy worldwide(account 
for 17% of economic loss caused by diseases in developing countries). Cervical 
ectopy is a common risk factor of STIs(including HIV and human papilloma virus 
infections), especially in developing countries. objeCtives: To assess the com-
parative safety and effectiveness of focused ultrasound(FU) and microwave(MW) 
for cervical ectopy. Methods: We searched Chinese Biomedical Literature data-
base (CBM), the Chinese Scientific Journals database (VIP),the China Academic 
Journals Full-text database (CNKI), MEDLINE, EMBASE, and Cochrane Library 
to July 31, 2013. Randomized controlled trials(RCTs) or clinical controlled 
trials(CCTs) were included. Two reviewers independently screened for eligi-
ble studies, extracted data and assessed risk of bias. We assessed the quality of 
included studies using criteria from Cochrane Handbook 5.0.Statistical analysis 
was performed by RevMan 5.02 , a random-effect model was used in this meta-
analysis. Funnel plots and Egger’s regression analyses were used to evaluate 
the publication bias. We used GRADE to summarize the results. Results: We 
included 26 RCTs(n= 10058) and 13 CCTs(n= 6122) both with high risk of bias. 
Meta-analyses indicated: compared with MW: FU reduced the risk of vaginal bleed 
(RCTs:RR= 0.12,95%CI [0.05-0.29]; CCTs:RR= 0.15,95%CI [0.09-0.25]) and vaginal dis-
charge (RCTs:RR= 0.30,95%CI [0.19-0.47];CCTs:RR= 0.45,95%CI [0.25-0.82]); increased 
cure rate (RCTs;RR= 1.07,95%CI [1.02-1.13];CCTs:RR= 1.16,95%CI [1.01-1.32]) and total 
effective rate (RCTs:RR= 1.04,95%CI [1.02-1.07];CCTs:RR= 1.07,95%CI [0.96-1.20]); 
decreased recurrence rate (RCTs;RR= 0.06,95%CI [0.01-0.45];CCTs:RR= 0.11,95%CI 
[0.02-0.67]). Egger’s regression analyses and funnel plots suggested likely publica-
tion bias in the safety studies. All safety and effective indicators were very low qual-
